Sana Biotechnology (SANA) Current Leases (2020 - 2026)

Sana Biotechnology has disclosed Current Leases across 7 years of filings, most recently posting $14.9 million for Q1 2026.

• Current Leases for Q1 2026 came in at $14.9 million, up 14.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 14.42% YoY), and the FY2025 annual result was $14.9 million, up 19.18% from the prior year.
• Current Leases came in at $14.9 million for Q1 2026 at Sana Biotechnology, roughly flat from $14.9 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $14.9 million in Q4 2025 to a low of $9.6 million in Q1 2022.
• The 5-year median for Current Leases is $12.9 million (2023), against an average of $12.6 million.
• Across the five-year window, Current Leases jumped 146.42% in 2022 and decreased 22.44% in 2024, its largest moves.
• Sana Biotechnology's Current Leases stood at $12.4 million in 2022, then increased by 6.47% to $13.2 million in 2023, then fell by 5.01% to $12.5 million in 2024, then grew by 19.18% to $14.9 million in 2025, then slipped by 0.4% to $14.9 million in 2026.
• The last three Current Leases figures came in at $14.9 million (Q1 2026), $14.9 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.